CliffBio
biologic

Simponi

golimumab

Loss of exclusivityApril 2021projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameSimponi
Active ingredientgolimumab
Strength50MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2009
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Simponi patent cliff — loss of exclusivity April 2021 | CliffBio